$VYNE News
Last published 3mo ago
- 3mo agoVYNEVYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow BioscienceGlobeNewswireNEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that its previously announced special cash dividend (the "Cash
- 3mo agoVYNEVYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow BioscienceGlobeNewswireNEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has approved a reverse stock split of VYNE’s
- 4mo agoVYNEVYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow BioscienceGlobeNewswireNEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the
- 11mo agoVYNEVYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementGlobeNewswireFollowing closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye
- 1y agoVYNEVYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateGlobeNewswireCompany is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strategic
- 1y agoVYNEVYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business UpdateGlobeNewswireBRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat
- 1y agoVYNEVYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental VitiligoGlobeNewswireTrial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI
- 1y agoVYNEVYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202GlobeNewswireBRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat
- 1y agoVYNEVYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business UpdateGlobeNewswireRepibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or
- 1y agoVYNEVYNE Therapeutics Provides Update on VYN202 ProgramGlobeNewswireBRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that
- 1y agoVYNEVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewswireBRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat
- 1y agoVYNEVYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business UpdateGlobeNewswireRepibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025Expected cash runway into 2H 2026 BRIDGEWATER, N.J.,
- 1y agoVYNEVYNE Therapeutics to Participate in March Investor ConferencesGlobeNewswireBRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat
- 1y agoVYNEVYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque PsoriasisGlobeNewswireOral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designed to provide
- 1y agoVYNEVYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental VitiligoGlobeNewswireOnce-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in mid-2025"Repibresib" approved as the non-proprietary name for
- 1y agoVYNEVYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET InhibitorGlobeNewswirePromising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and
- 2y agoVYNEVYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireVYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD
- 2y agoVYNEVYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET InhibitorGlobeNewswireVYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and
- 2y agoVYNEVYNE Therapeutics to Participate in September Investor ConferencesGlobeNewswireBRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat
- 2y agoVYNEVYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireInitiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected in Q3 and Q4 2024,
- 2y agoVYNEVYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET InhibitorGlobeNewswireBRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated
- 2y agoVYNEVYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical DevelopmentGlobeNewswireBRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated
- 2y agoVYNEVYNE Therapeutics to Participate in Leerink Partners Therapeutics ForumGlobeNewswireBRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated
- 2y agoVYNEVYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202GlobeNewswireVYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line data expected in
- 2y agoVYNEVYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201GlobeNewswireTrial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 BRIDGEWATER, N.J.,
- 2y agoVYNEVYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireDesign of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarterPhase 2b trial expected to enroll approximately 160 subjects with either active or stable nonsegmental vitiligo and
- 2y agoVYNEVYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET InhibitorGlobeNewswireIn preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD
- 2y agoVYNEVYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual MeetingGlobeNewswirePresentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE)
- 2y agoVYNEVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewswireBRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and
- 2y agoVYNEVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateGlobeNewswire2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investorsAnticipate commencing a
- 2y agoVYNEVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumGlobeNewswireOral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the
- 2y agoVYNEVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewswireBRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated
- 2y agoVYNEVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of VitiligoGlobeNewswireVYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201's rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase 2b initiation in Q2
- 2y agoVYNEVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of DirectorsGlobeNewswireBRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated
- 3y agoVYNEVYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireTransformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental
- 3y agoVYNEVYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023GlobeNewswireEvent will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE's clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo
- 3y agoVYNEVYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 MillionGlobeNewswireBRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated
- 3y agoVYNEVYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202GlobeNewswireTreatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion of recent financing,
- 3y agoVYNEVYNE Therapeutics Announces Private Placement of $88 MillionGlobeNewswireBRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated
- 3y agoVYNEVYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental VitiligoGlobeNewswireClinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally
- 3y agoVYNEVYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireBRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and
- 3y agoVYNEVYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireAnticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small
- 3y agoVYNEVYNE Therapeutics to Attend BIO International ConventionGlobeNewswireBRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and
- 3y agoVYNEVYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireAnticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential
- 3y agoVYNEVYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary FibrosisGlobeNewswireVYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placeboReduction in lung fibrosis from VYN201 treatment resulted in
- 3y agoVYNEVYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201GlobeNewswireNo quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports "soft" drug approach for topical pan-BD BET inhibitor All hematological parameters, including platelet counts, were
- 3y agoVYNEVYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual ConferenceGlobeNewswireBRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and
- 3y agoVYNEVYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business UpdateGlobeNewswireFirst vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09, 2023 (GLOBE
- 3y agoVYNEVYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleGlobeNewswireBRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and
- 3y agoVYNEVYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care ConferenceGlobeNewswireBRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated